Your cart is currently empty!.
You may check out all the available products and buy some in the shop.
Continue Shopping
Pfizer Inc (PFE) (Q4FY24) – Advancing innovation while navigating market challenges
$232.00
Pfizer successfully integrated the Seagen business, one of its largest investments in the past decade, strengthening its position as a leading oncology company. The company earned the top spot in the 2024 IQVIA US Field Force Ranking and ranked first or second in 70% of its key specialties.
Description
Description
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.
Pfizer’s fourth quarter 2024 revenue was $17.8 billion, an increase of $3.2 billion (22%) from the prior year, primarily due to a one-time, non-cash Paxlovid revenue reversal of $3.5 billion recorded in Q4 2023.
Pfizer in the last 3 months the stock has given a negative return of (1%), the stock price decreased to $26.05 as of Mar 17, 2025, from $26.43 as of Dec 17, 2024.
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/pfizer-equity-report-q3-24/
